US biotech Mustang Bio says that an investigator-led trial of its CAR-T therapy for multiple myeloma – the first to target CS1 protein – has started recruiting patients.
European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.
It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership with MaxCyte, and Precision BioSciences filing for a $100 million IPO for its ‘off-the-sh